Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized Neoantigen Vaccine (Washington University School of Medicine)
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- Peptides, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
A personalized neoantigen vaccine platform developed by Washington University School of Medicine for the treatment of pediatric patients with recurrent or refractory brain tumors. The vaccine is tailored to each patient by identifying unique tumor mutations (neoantigens) through exome and cDNA-capture sequencing of tumor and normal tissue. It is designed to target up to 20 prioritized patient-specific neoantigens to stimulate a robust T-cell mediated immune response. The platform encompasses both polyepitope DNA plasmid vaccines, typically delivered via electroporation (e.g., using the TDS-IM v2.0 device), and synthetic long peptide vaccines. These vaccines are generally administered in combination with the adjuvant poly-ICLC (Hiltonol), a Toll-like receptor 3 (TLR3) agonist, to enhance dendritic cell activation and overall immunogenicity.
- Other names
- Personalized neoantigen DNA vaccinePersonalized neoantigen peptide vaccineNeoepitope-based personalized vaccinePolyepitope DNA vaccineo-Washington University School of Medicine-pediatric brain tumor
02
Targets
neoAg-MHC (Patient-specific tumor neoantigen–Major Histocompatibility Complex)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on Personalized Neoantigen Vaccine (Washington University School of Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized Neoantigen Vaccine (Washington University School of Medicine).